Barry J. Sugarman

3.2k citations

31 papers · 2.7k indexed · 1 hit paper · h-index 18

Molecular Biology top 5%
Immunology top 5%
Oncology top 5%
Genetics top 5%
Cancer Research top 10%

Co-authors: H. Michael Shepard Bharat B. Aggarwal Philip E. Hass Irene S. Figari Michael A. Palladino Jerry B. Dodgson James Douglas Engel Paul Shabram
Topics: Virus-based gene therapy research (11 papers)Proteoglycans and glycosaminoglycans research (7 papers)RNA Interference and Gene Delivery (6 papers)
Cited by: Immunology Oncology Genetics
Journals: Nature Science Cell
Partner nations: United States Switzerland Netherlands

In The Last Decade

Barry J. Sugarman

31 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro

1985 1.4k citations Barry J. Sugarman, H. Michael Shepard et al. profile →

Peers

Countries citing papers authored by Barry J. Sugarman

Since Specialization

Citations

This map shows the geographic impact of Barry J. Sugarman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry J. Sugarman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry J. Sugarman more than expected).

Fields of papers citing papers by Barry J. Sugarman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry J. Sugarman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry J. Sugarman. The network helps show where Barry J. Sugarman may publish in the future.

Co-authorship network of co-authors of Barry J. Sugarman

This figure shows the co-authorship network connecting the top 25 collaborators of Barry J. Sugarman. A scholar is included among the top collaborators of Barry J. Sugarman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry J. Sugarman. Barry J. Sugarman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer 2021 ·PLoS ONE ·David W. Kang,Beate Bittner,Barry J. Sugarman,Monica L. Zepeda,Marie A. Printz	9
2	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers 2020 ·Current Therapeutic Research ·Marie A. Printz,Samuel S. Dychter,(unknown),(unknown),Barry J. Sugarman,Monica L. Zepeda,(unknown),David W. Kang,Daniel C. Maneval	17
3	Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration 2015 ·The AAPS Journal ·Sanna Rosengren,Samuel S. Dychter,Marie A. Printz,Lei Huang,Richard I. Schiff,(unknown),(unknown),Fred H. Drake,(unknown),(unknown),G. J. Frost,Barry J. Sugarman,Douglas B. Muchmore	44
4	Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers 2014 ·Clinical Therapeutics ·Samuel S. Dychter,(unknown),(unknown),Marie A. Printz,Barry J. Sugarman,(unknown),David B. Haughey,(unknown),Daniel C. Maneval	16
5	Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys 2011 ·Gene Therapy ·(unknown),Narendra S. Kishnani,Jacob Nelson,(unknown),Dara W. Frank,(unknown),Lin Xie,(unknown),(unknown),C Rosenfeld,Jeffrey A. Hubbell,Stephen E. Maxwell,Barry J. Sugarman,Beth Hutchins,Daniel C. Maneval,Kimberley A. Treinen	1
6	Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models 2010 ·Molecular Cancer Therapeutics ·Curtis B. Thompson,H. Michael Shepard,P M O'Connor,Salam Kadhim,Ping Jiang,Ryan J. Osgood,Louis H. Bookbinder,Xiaoming Li,Barry J. Sugarman,Robert Connor,(unknown),G. J. Frost	235
7	Accelerated Pharmacokinetics and Glucodynamics of Prandial Insulins Injected With Recombinant Human Hyaluronidase 2009 ·Diabetes Technology & Therapeutics ·Daniel E. Vaughn,Richard C. Yocum,Douglas B. Muchmore,Barry J. Sugarman,Andrew Vick,(unknown),G. J. Frost	41
8	Tumor Growth Inhibition by Interferon-α using PEGylated Protein or Adenovirus Gene Transfer with Constitutive or Regulated Expression 2002 ·Molecular Therapy ·G W Demers,Duane E. Johnson,Todd Machemer,(unknown),(unknown),(unknown),Barry J. Sugarman,John A. Howe	4
9	Interferon-α2b Secretion by Adenovirus-Mediated Gene Delivery in Rat, Rabbit, and Chimpanzee Results in Similar Pharmacokinetic Profiles 2002 ·Toxicology and Applied Pharmacology ·G W Demers,Barry J. Sugarman,(unknown),(unknown),C. M. Iqbal Ahmed,Johnson Y.N. Lau,Zhi Hong,Robert E. Lanford,Daniel C. Maneval	15
10	Selective Expression of Nonsecreted Interferon by an Adenoviral Vector Confers Antiproliferative and Antiviral Properties and Causes Reduction of Tumor Growth in Nude Mice 2001 ·Journal of Interferon & Cytokine Research ·C. M. Iqbal Ahmed,Ken N. Wills,Barry J. Sugarman,Duane E. Johnson,Murali Ramachandra,(unknown),John A. Howe	27
11	Enhanced Apoptotic Activity of a p53 Variant in Tumors Resistant to Wild-Type p53 Treatment 2001 ·Molecular Therapy ·Isabella Atencio,Jenny B. Avanzini,Duane E. Johnson,Saskia Neuteboom,(unknown),Loretta L. Nielsen,(unknown),Suganto Sutjipto,Barry J. Sugarman,Jennifer Philopena,(unknown),(unknown),(unknown),Murali Ramachandra,Ken N. Wills	7
12	Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers 2001 ·Cancer Gene Therapy ·C. M. Iqbal Ahmed,Duane E. Johnson,G W Demers,(unknown),John A. Howe,Ken N. Wills,Shu-Fen Wen,(unknown),(unknown),(unknown),Todd Machemer,(unknown),(unknown),Barry J. Sugarman	33
13	Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy 2001 ·Nature Biotechnology ·Murali Ramachandra,Amena Rahman,Aihua Zou,Mei Vaillancourt,John A. Howe,(unknown),Barry J. Sugarman,G W Demers,Heidrun Engler,Duane E. Johnson,Paul Shabram	113
14	In Vivo Tumor Suppression by Adenovirus-Mediated Interferon alpha2b Gene Delivery 1999 ·Human Gene Therapy ·C. M. Iqbal Ahmed,Barry J. Sugarman,Duane E. Johnson,(unknown),(unknown),(unknown),Ken N. Wills	21
15	Comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy 1998 ·Cytometry ·(unknown),Shijun Cui,David A.P. Small,(unknown),Barry J. Sugarman,Michael J. Grace	31
16	Analytical Anion-Exchange HPLC of Recombinant Type-5 Adenoviral Particles 1997 ·Human Gene Therapy ·Paul Shabram,(unknown),(unknown),Richard J. Gregory,Mark Horn,Bernard Huyghe,(unknown),Mary H. Nunnally,Barry J. Sugarman,Suganto Sutjipto	164
17	Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column Chromatography 1995 ·Human Gene Therapy ·Bernard Huyghe,Xiaodong Liu,Suganto Sutjipto,Barry J. Sugarman,Mark Horn,H. Michael Shepard,Carl J. Scandella,Paul Shabram	159
18	Recombinant Human Transforming Growth Factor-β1: Expression by Chinese Hamster Ovary Cells, Isolation, and Characterization 1993 ·Protein Expression and Purification ·(unknown),Chih-Wei Lin,Scott L. Lauren,(unknown),Barry J. Sugarman,S. Hu,Keith R. Westcott	17
19	Synergistic induction of polypeptides by tumor necrosis factor and interferon‐gamma in cells sensitive or resistant to tumor necrosis factor: Assessment by computer based analysis of two‐dimensional gels using the PDQUEST system 1990 ·Electrophoresis ·Maureen H. Beresini,Barry J. Sugarman,H. Michael Shepard,Lois B. Epstein	18
20	Chromosomal arrangement of the chicken β-type globin genes 1981 ·Cell ·Maureen Dolan,Barry J. Sugarman,Jerry B. Dodgson,James Douglas Engel	80

About Barry J. Sugarman

Barry J. Sugarman is a scholar working on Cell Biology, Genetics and Biotechnology, having authored 31 papers that have together received 2.7k indexed citations. Recurring topics across this work include Virus-based gene therapy research (11 papers), Proteoglycans and glycosaminoglycans research (7 papers) and RNA Interference and Gene Delivery (6 papers). The work is most often cited by research in Immunology (844 citations), Oncology (676 citations) and Genetics (665 citations). Barry J. Sugarman has collaborated with scholars based in United States, Switzerland and Netherlands. Frequent co-authors include H. Michael Shepard, Bharat B. Aggarwal, Philip E. Hass, Irene S. Figari, Michael A. Palladino, Jerry B. Dodgson, James Douglas Engel, Paul Shabram, Suganto Sutjipto and Bernard Huyghe. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact